.jpg)
.png)
All
I am honored and truly humbled to have the opportunity to serve as the President of the National Lipid Association (NLA) during the 2014/2015 term. In just a few months as president, I’ve seen tremendous strides in the lipid community, which I only hope to continue during the remainder of my... more
This issue sponsored by the Pacific Lipid Association Featuring: "The PCSK9 Revolution: Hope or Hype? Latest Clinical Trial Results and Implications" and "Identifying Risk from Coronary Calcium Scoring" more
A Review of USPSTF Recommendations for Use of Novel Markers in Risk Stratification Risk Stratification of Dyslipidemia in the Pediatric Population
EBM Tools for Practice: A Positive Approach for Cardioprotective Eating with the Mediterranean Diet Clinical Use of Pedometers in Cardiometabolic Risk Reduction Programs
The National Lipid Association's (NLA) Annual Summary of Clinical Lipidology 2016 was just published the Journal of Clinical Lipidology. This year's summary enhances the NLA's established commitment to a patient-centered approach and individualized care, which is an approach now... more
According to the 2011 National Diabetes fact sheet, 25.8 million adults and children in the United States (8.3%) have diabetes and 79 million have pre-diabetes. In 2010 alone, 1.9 million new cases of diabetes were diagnosed. In 2007, the total cost of diagnosed diabetes was $174 billion and... more
Clinical Insights: Metabolic Syndrome- A Useful Clinical Marker of Increased Risk for Type 2 Diabetes and Cardiovascular Disease
...the times they are a-changin' ~Bob Dylan These are exciting times for Lipidologists! We can always count on change as the one sure thing in life. Our field is changing. As health care evolves, the NLA is doing its part to position our field to take advantage of the changes that our system... more
As a logged in user, you will see a My Account link at the top left corner of the page. Clicking this will bring you to your profile page. Once there, you can click the edit tab; and then the Member Record Button.
On April 23, Amarin Corp. issued a press release announcing that the U.S. FDA has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high... more